Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Abeona Therapeutics (Nasdaq: ABEO) reported that its Compensation Committee granted equity awards to new non-executive employees under Nasdaq Listing Rule 5635(c)(4). On August 31, 2026, Abeona approved restricted stock awards covering up to an aggregate of 13,300 shares of common stock for five new hires. These inducement awards vest in three equal annual installments on each anniversary of the grant date, contingent on the employees’ continued employment, and are intended as a material inducement to join the company.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 13 | Q2 earnings report | Positive | -14.9% | Revenue increased quarter over quarter, but the stock recorded a negative 24-hour reaction. |
| Aug 06 | Earnings call scheduling | Neutral | +1.5% | Company scheduled its second-quarter results conference call and corporate update. |
| Aug 04 | Reimbursement designation | Positive | +6.7% | CMS granted NTAP status for ZEVASKYN under the Fiscal Year 2027 rule. |
| Aug 03 | Employee inducement grants | Neutral | -0.5% | Abeona granted restricted shares to new employees with three-year vesting. |
| Jul 21 | Treatment center activation | Positive | +0.8% | Cincinnati Children's became the seventh qualified treatment center for ZEVASKYN. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive operational and regulatory announcements generally aligned with gains, while the Q2 earnings release diverged with a -14.95% reaction.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock equity awards financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On August 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to five individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 13,300 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards is scheduled to vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee are scheduled to be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Contacts: Investor and Media: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com Investor: Lee M. Stern Meru Advisors lstern@meruadvisors.com